Drug intelligence / Profile preview

KUP101

Development stage: Phase 1
Lead developer: Kupando
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

KUP101 is Kupando's clinical-stage **dual Toll-like receptor 4 and Toll-like receptor 7 agonist** immunotherapy. It is a liposomal product containing two co-encapsulated small-molecule agonists intended to stimulate innate immunity and induce trained innate immunity. KUP101 is being evaluated in a first-in-human Phase 1 study for advanced solid tumors, including advanced skin cancers, and is also being developed preclinically as a host-directed approach for infectious diseases, including antimicrobial-resistant infections.

Targets

TLR7 (Toll-like receptor 7)TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on KUP101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KUP101.

Explore the full profile